OBJECTIVE We aimed to investigate the added value of interstitial brachytherapy (IS-BT) over classical intracavitary BT (IC-BT) in terms of target coverage and organ at risk (OAR) sparing among patients for whom an optimal dose distribution could not be provided without IS-ICBT and also to determine if the magnitude advantage provided by IS-BT is similar in patients smaller (
📌 3 Key Takeaways
🎯
Objective & Hypothesis:OBJECTIVE We aimed to investigate the added value of interstitial brachytherapy (IS-BT) over classical intracavitary BT (IC-BT) in terms of target coverage and organ at risk (OAR) sparing among patients for whom an optimal dose distribution could not be provided without IS-ICBT and also to determine if the magnitude advantage provided by IS-BT is similar in patients smaller (
📊
Key Findings & Data:OBJECTIVE We aimed to investigate the added value of interstitial brachytherapy (IS-BT) over classical intracavitary BT (IC-BT) in terms of target coverage and organ at risk (OAR) sparing among patients for whom an optimal dose distribution could not be provided without IS-ICBT and also to determine if the magnitude advantage provided by IS-BT is similar in patients smaller (
💡
Conclusion & Impact:OBJECTIVE We aimed to investigate the added value of interstitial brachytherapy (IS-BT) over classical intracavitary BT (IC-BT) in terms of target coverage and organ at risk (OAR) sparing among patients for whom an optimal dose distribution could not be provided without IS-ICBT and also to determine if the magnitude advantage provided by IS-BT is similar in patients smaller (
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Abstract
OBJECTIVE We aimed to investigate the added value of interstitial brachytherapy (IS-BT) over classical intracavitary BT (IC-BT) in terms of target coverage and organ at risk (OAR) sparing among patients for whom an optimal dose distribution could not be provided without IS-ICBT and also to determine if the magnitude advantage provided by IS-BT is similar in patients smaller (
🔖
Cite This Article
TAMBAŞ, M. (2022). Therapeutic Benefit of Intracavitary-interstitial Brachytherapy in Cervical Cancer Patients with Small and Large High-risk Clinical Target Volume. Türk Onkoloji Dergisi, Cilt: 36 - Sayı: 4, 431–437. https://ajindex.com/articles/655151
Fokdal L, Sturdza A, Mazeron R, Haie-Meder C, Tan LT, Gillham C, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiother Oncol 2016;120(3):434–40
Nomden CN, de Leeuw AA, Moerland MA, Roesink JM, Tersteeg RJ, Jurgenliemk-Schulz IM. Clinical use of the Utrecht applicator for combined intracavitary/ interstitial brachytherapy treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2012;82(4):1424–30
Jurgenliemk-Schulz IM, Tersteeg RJ, Roesink JM, Bijmolt S, Nomden CN, Moerland MA, et al. MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer. Radiother Oncol. 2009;93(2):322–30
Kirisits C, Lang S, Dimopoulos J, Berger D, Georg D, Potter R. The Vienna applicator for combined intracav itary and interstitial brachytherapy of cervical cancer: Design, application, treatment planning, and dosimetric results. Int J Radiat Oncol Biol Phys 2006;65(2):624–30
Tambas M, Tavli B, Bilici N, Dizman A, Sertel H, Fayda M. Computed tomography-guided optimization of needle insertion for combined intracavitary/ interstitial brachytherapy with utrecht applicator in locally advanced cervical cancer. Pract Radiat Oncol 2021;11(4):272–81
Haie-Meder C, Potter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (I): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005;74(3):235–45
Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D imagebased treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006;78(1):67–77
Hellebust TP, Kirisits C, Berger D, Perez-Calatayud J, De Brabandere M, De Leeuw A, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group: Considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radioth